Form 4 for ARTV Artiva Biotherapeutics, Inc.
Accepted 2026-09-04 16:04:03 ET · period of report 2026-09-03 · accession 0001193125-26-383625 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-04 16:04 | 2026-09-03 | ARTV | Horan Christopher | Chief Tech Ops Off | S - Sale | $11.16 | -10.4K | 283.1K | -4% | -$115.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-03 | S | D | 10,366 | $11.16 | 283,084 | D | — | — | (F1) The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. (F2) The weighted average sale price for the transaction reported was $11.1555, and the range of prices were between $11.0301 and $11.1556. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |